wednesday, october 28 | 4:00pM ET

Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.

Featured Key Opinion Leader

Jonathan Graf, MD
Professor of Medicine at the University of California San Francisco

Dr. Graf is a Professor in the Department of Medicine at the University of California San Francisco (UCSF) in the division of rheumatology at Zuckerberg San Francisco General. He is board certified in rheumatology, receiving his MD degree from the University of Pennsylvania and completing his residency and fellowship training at the UCSF School of Medicine. He has been a practicing rheumatologist for nearly 20 years and co-founded the UCSF rheumatoid arthritis (RA) cohort in 2006. He is co-author on numerous publications in the field of rheumatology and has been an investigator on multiple clinical trials related to rheumatoid arthritis. He currently receives research support from Navidea as one of the lead investigators for the NAV3-31 trial in RA, and he has been involved in the design and execution of this and other clinical trials of Tilmanocept in RA.

Management

Jed A. Latkin
Chief Executive Officer, Chief Financial Officer and
Chief Operating Officer
  • Previously was a Portfolio Manager at Nagel Avenue Capital beginning 2010 and at ING Investment Management from 2006-2010, Morgan Stanley Investment banking (2002-2006)

  • Previously served as CFO of Viper Powersports, CEO of End of Life Petroleum Holdings, CEO of Black Elk Energy, Portfolio Manager of Precious Capital and CFO of West Ventures

  • Currently serves on the boards of the Renewable Fuels Association and Buffalo Lake Advanced Biofuels

  • MBA finance - Columbia Grad School of Business

Michael Rosol, Ph.D.
Chief Medical Officer

Prior to joining Navidea, Dr. Rosol served as Associate Director in the Clinical and Translational Imaging Group at Novartis Institutes for BioMedical Research from November 2016 to December 2018. Before that, he held positions as Senior Director of Business Development at Elucid Bioimaging, Inc. where he drove adoption of its Computer-Aided Phenotyping applications from May 2016 to November 2016, and as Chief Scientific Officer of MediLumine, Inc. from October 2015 to May 2016. Prior to those roles, he was the Head of the Translational Imaging Group at Novartis Pharmaceuticals Group from October 2012 to March 2015. His training and experience lie in the fields of biophysics, physiology, and biological/medical imaging, and his work has focused on cardiovascular imaging, preclinical and clinical imaging instrumentation and applications, animal models of human disease, pathophysiology, biomarkers, and imaging in toxicological and clinical trials. He has also served as faculty in Radiology and Director of two academic research imaging facilities. Dr. Rosol holds a PhD from Boston University School of Medicine.

JTC_noText.png
Moderated by:
Jenene Thomas, CEO, JTC Team
© 2020 Virtual Investor. All rights reserved.
HeaderImage_10.22.20.png